Treatment time-courses reveal sequential activation patterns, with initial VEGFR2 phosphorylation preceding downstream FAK and paxillin activation
Long-term studies show that continuous drug dependence, gastrointestinal side effects, and rebound weight gain are common once treatment stops
Satoh, T., Sakai, N., Enokido, Y., Uchiyama, Y
State participation in the Medicaid Drug Rebate Program requires coverage of nearly all FDA-approved drugs for medically accepted indications, but weight-loss drugs are included in a small group of drugs that can be excluded from coverage
Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline